Wilson Sy
Neurology with Special Qualifications in Child Neurology · Edinburg, TXNPI 1588726749
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,265 of the $9,317 with a category attached, or 67.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2020 at $3,028 and has fallen 95.9% since, to $125 in 2025.
Across 274 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$2K
- Supernus Pharmaceuticals, Inc.$1K
- Neurelis, Inc.$1K
- UCB, Inc.$1K
- Ironshore Pharmaceuticals Inc.$489
- Eisai Inc.$473
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,16023%
- Speaking & faculty fees$8599%
- Food & beverage$6,26567%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 1 | $2,160 |
| Supernus Pharmaceuticals, Inc. | 69 | $1,379 |
| Neurelis, Inc. | 15 | $1,241 |
| UCB, Inc. | 45 | $1,132 |
| Ironshore Pharmaceuticals Inc. | 17 | $489 |
| Eisai Inc. | 23 | $473 |
| SK Life Science, Inc. | 14 | $402 |
| Sunovion Pharmaceuticals Inc. | 20 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $241 |
| Corium, LLC | 6 | $219 |
| Livanova USA, Inc. | 4 | $206 |
| Zogenix Inc. | 7 | $176 |
| Tris Pharma Inc | 8 | $172 |
| Greenwich Biosciences, Inc. | 5 | $144 |
| Biogen | 2 | $125 |
| Biocodex, Inc. | 3 | $83 |
| Immedica Pharma US, Inc. | 3 | $75 |
| Sumitomo Pharma America, Inc. | 4 | $70 |
| Upsher-smith Laboratories LLC | 2 | $48 |
| Shire North American Group Inc | 3 | $42 |
| Biomarin Pharmaceutical Inc. | 3 | $39 |
| Aquestive Therapeutics, Inc. | 2 | $33 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| PTC Therapeutics, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Novartis | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,317 in reported general payments places this provider in the 85th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 12 | $774 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Edinburg
- Priti ManoharEdinburg$13K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Kaitlin BatleyDallas$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.